Approval · Notice of Compliance 16619 · 2015
VECTIBIX: Notice of Compliance 16619
Issued February 19, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16619
- Date
- February 19, 2015
- Company
- Amgen Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Fulfillment of conditions as per the letter of undertaking dated april 2, 1008 for monotherapy for the treatment of patients with egfr-expressing metastatic colorectal carninoma (mcrc) with non-mutated (wild type) kras after failure of fluoropyrimidine-,oxaliplatin-, and irinotecan-containing chemotherapy regimens
- Therapeutic class
- Antineoplastic
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VECTIBIX | Not yet assigned | — |
Medicinal ingredients
- PANITUMUMAB 20 MG per ML